A T-cell based COVID vaccine may last longer than the current jabs, providing long-lasting immunity against future emerging variants and could be used as a model for other seasonal viral diseases like the flu, an Indian-American researcher has revealed.

Focusing on the T-cell instead, Pennsylvania State University researchers in the US partnered with Evaxion Biotech on a study that was the first to demonstrate the effectiveness of an AI-generated vaccine in a live viral challenge model.